

Haematological Cancer Diagnostic Partnership: The new GM-wide diagnostic service for haematological cancers

Presented on behalf of the Haem-Onc. Pathway Board and GM Cancer

Dr Eleni Tholouli, Haemato-oncology Clinical Director GM Cancer - Eleni.Tholouli@mft.nhs.uk

Michelle Leach, Haemato-oncology Pathway Manager GM Cancer - Michelle.leach1@nhs.net

Introduction

NICE recommended Improving Outcomes Guidance (IOG) for Haem-Onc requires a centralised diagnostic integrated reporting system. Following an external review of GM a service build on the complementary strengths of Manchester Foundation Trust and Christie Foundation Trust to provide a GM wide solution within a clear commissioning framework was considered most appropriate, offering a cost-effective service with integrated diagnostic pathways.

Manchester Haematological Cancers Diagnostic Partnership

From www.haemologyetc.co.uk

Welcome to the help and information pages for the Manchester HCDC Service, please select an icon

Click symbol to enter index



Partnership

The established HCDC service has the following partnership principles and governance shared by the two provider organisations and our clients:

1. Patients
2. Clinical users
3. Research and Clinical Trials
4. Laboratory services

Communication

An integrated IT system has been introduced that brings together laboratories across GM, and provides web-based access for users during all stages of the reporting process.

The service will support common standards agreed between staff at different sites supported by clear information and SOPs described within our IT platform.

The service will employ real-time monitoring of time to report, report quality and audit, to meet the standards of our users and to provide early warning of problems.

Support for users

Information about diagnostic tests and the interpretation of reports is provided through the Wiki-based support system.

Practical service support is also provided via Wiki: with communication links, transport arrangements, and IT support including mechanism to access urgent transport and diagnosis.

MDT support and personal telephone support will be provided for all users.

Education and Support

Educational resources are provided to support our users looking to understand and make best use of new testing modalities or to assist their local practice.

Support for patients seeking to understand the diagnostic procedures, how tests work and how laboratory reports are also generated.

A site for dissemination of Clinical Trials availability and contacts for recruitment and to request research samples.

Outcomes

The combined work of MFT and CFT together with GM Partners have developed a Cancer Standards compliant diagnostic service for haematology in Greater Manchester. We continue our focus on quality and communication aiming to meet and exceed the requirements for patients and clinicians in Greater Manchester.

References

1. NICE Improving Outcomes Guidance (IOG) for Haem-Onc May 2016
2. NICE Improving Outcomes Guidance (IOG) for Haem-Onc 2013
3. Robin Ireland. GM Cancer: Review of Integrated Diagnostic Services for Haematological Malignancies. Oct 2017

1. Practical support – an integrated transport and specimen reception



2. Supporting laboratories and users: examples from our molecular pages

Myeloid Panel (NGS)

From www.haemologyetc.co.uk

This area describes the major genetic mutations screened by our NGS Panel for myeloid disorders.

Please note that the information is provided for initial guidance only. While we keep the information as up to date as possible, those taking clinical decisions should also consult other sources.

This is a 40 gene panel:

1. Colour indicates major associated processes - see key

Panel genes are listed in alphabetical order - Click gene name for further information




Key
 Navy: 1. Genes associated predominantly with epigenetic processes
 Green: 2. Genes associated predominantly with gene transcription
 Orange: 3. Genes associated predominantly with cell signaling
 Grey: 4. Genes associated predominantly with Tumour suppression functions
 Blue: 5. Genes associated predominantly with DNA repair functions
 Red: 6. Genes with multiple functions other protein biosynthesis or cell division

3. Education and decision support – added value

Use of panels in B-LPD

Presented are the most frequent patterns of marker expression for the different disorders; it is however recognised that there is considerable potential variation. The potential variability is discussed in the disease-specific sections.



Red Cell Morphology

Can flag a P10 flag

abnormal erythrocyte maturation, size or haemoglobin content

